Caxton Associates (New York)’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-55,745
| Closed | -$1.04M | – | 582 |
|
|
2024
Q1 | $1.04M | Sell |
55,745
-64,036
| -53% | -$1.2M | 0.06% | 210 |
|
|
2023
Q4 | $2.6M | Buy |
119,781
+51,746
| +76% | +$1.12M | 0.13% | 93 |
|
|
2023
Q3 | $1.4M | Buy |
+68,035
| New | +$1.4M | 0.19% | 96 |
|
|
2022
Q3 | – | Sell |
-18,426
| Closed | -$595K | – | 627 |
|
|
2022
Q2 | $595K | Buy |
+18,426
| New | +$595K | 0.06% | 216 |
|
|
2022
Q1 | – | Sell |
-17,550
| Closed | -$747K | – | 643 |
|
|
2021
Q4 | $747K | Buy |
17,550
+6,190
| +54% | +$263K | 0.08% | 155 |
|
|
2021
Q3 | $503K | Buy |
+11,360
| New | +$503K | 0.06% | 181 |
|